etomoxir has been researched along with Arrhythmias, Cardiac in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baartscheer, A; Bezzina, CR; Bleeker, JC; Coronel, R; Ferdinandusse, S; Guan, K; Houtkooper, RH; IJlst, L; Knottnerus, SJG; Li, W; Luo, X; Mengarelli, I; Portero, VM; Ulbricht, Y; Verkerk, AO; Visser, G; Wanders, RJA; Wijburg, FA; Wüst, RCI | 1 |
| Eteraf Oskouei, T; Garjani, A; Maleki, N; Najafi, M | 1 |
2 other study(ies) available for etomoxir and Arrhythmias, Cardiac
| Article | Year |
|---|---|
Electrophysiological Abnormalities in VLCAD Deficient hiPSC-Cardiomyocytes Can Be Improved by Lowering Accumulation of Fatty Acid Oxidation Intermediates.
Topics: Action Potentials; Acyl-CoA Dehydrogenase, Long-Chain; Arrhythmias, Cardiac; Cardiac Electrophysiology; Congenital Bone Marrow Failure Syndromes; Epoxy Compounds; Fatty Acids; Humans; Induced Pluripotent Stem Cells; Lipid Metabolism, Inborn Errors; Mitochondria; Mitochondrial Diseases; Muscular Diseases; Myocytes, Cardiac; Oxidation-Reduction; Resveratrol | 2020 |
Antiarrhythmic and arrhythmogenic effects of L-carnitine in ischemia and reperfusion.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Carnitine; Coronary Occlusion; Epoxy Compounds; Glucose; Heart; Male; Myocardial Contraction; Myocardial Reperfusion Injury; Random Allocation; Rats; Rats, Sprague-Dawley; Tachycardia, Ventricular; Tromethamine; Ventricular Fibrillation; Ventricular Premature Complexes | 2008 |